Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MM09
Therapeutic Area : Immunology
Study Phase : Phase II/ Phase III
Sponsor : LAT Research | Xolomon Tree S.L.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 07, 2022
Lead Product(s) : MM09
Therapeutic Area : Immunology
Highest Development Status : Phase II/ Phase III
Sponsor : LAT Research | Xolomon Tree S.L.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dermatophagoides Pteronyssinus
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : BioClever 2005 | NTS Hub S.L.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 02, 2022
Lead Product(s) : Dermatophagoides Pteronyssinus
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : BioClever 2005 | NTS Hub S.L.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MV130
Therapeutic Area : Undisclosed
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 26, 2022
Lead Product(s) : MV130
Therapeutic Area : Undisclosed
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MG01
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 24, 2021
Lead Product(s) : MG01
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MG01
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 18, 2021
Lead Product(s) : MG01
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dermatophagoides Pteronyssinus
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase III
Sponsor : BioClever 2005 | NTS Hub S.L.
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 06, 2021
Lead Product(s) : Dermatophagoides Pteronyssinus
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase III
Sponsor : BioClever 2005 | NTS Hub S.L.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bacmune
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 30, 2020
Lead Product(s) : Bacmune
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MM09
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : BioClever 2005
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 17, 2020
Lead Product(s) : MM09
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : BioClever 2005
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bactek-MV130
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : BioClever 2005
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 Infection
Details : Undisclosed
Product Name : Bactek-R
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 27, 2020
Lead Product(s) : Bactek-MV130
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : BioClever 2005
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dermatophagoides Pteronyssinus
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 25, 2016
Lead Product(s) : Dermatophagoides Pteronyssinus
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable